Dr. Leslie H. Boyce, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
At a glance
- Medical school
- Rutgers New Jersey Medical School (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Rutgers New Jersey Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
NC license 970025 -
Neurology Physician
NC license 9700025 -
Sleep Medicine (Psychiatry & Neurology) Physician
NC license 970025
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Raleigh Neurology Associates, P. A. (52 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 6 companies reported 15 payments worth $561 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $241 |
|---|---|
| Boston Scientific Corporation | $148 |
| Avadel Cns Pharmaceuticals, LLC | $54.81 |
| Axsome Therapeutics, Inc. | $53.00 |
| Harmony Biosciences LLC | $34.14 |
| BioMarin Pharmaceutical Inc. | $29.73 |
| Food and Beverage | $411 |
|---|---|
| Consulting Fee | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Jan 24, 2025 | Consulting Fee XYWAV; XYREM · NEUROLOGY | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $21,666 in research payments for these studies, mostly to the institutions running them.
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Eli Lilly and Company · Active, not recruiting · NCT04616326 - A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company · Active, not recruiting · NCT03432286 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatm…
Teva Pharmaceuticals USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.